ASCO

Takeda's Iclusig shows potential to become standard of care in acute lymphoblastic leukemia subtype
Takeda's Iclusig shows potential to become standard of care in acute lymphoblastic leukemia subtype
Fierce Pharma
Takeda
Iclusig
acute lymphoblastic leukemia
ALL
ASCO
Flag link:
ASCO: Takeda Oncology ready to stoke partnerships to fire up cancer-fighting pillar technologies
ASCO: Takeda Oncology ready to stoke partnerships to fire up cancer-fighting pillar technologies
Fierce Biotech
Takeda Oncology
ASCO
Flag link:
Gilead's Immunomedics settles over-hyped ASCO data mishap for $4M
Gilead's Immunomedics settles over-hyped ASCO data mishap for $4M
Endpoints
Immunomedics
Gilead Sciences
ASCO
breast cancer
Flag link:
AstraZeneca/Merck come out of ASCO GU with a big win over J&J in battle over prostate cancer franchises
AstraZeneca/Merck come out of ASCO GU with a big win over J&J in battle over prostate cancer franchises
Endpoints
AstraZeneca
Merck
JNJ
ASCO
prostate cancer
Lynparza
Flag link:
Pharmacist-driven biosimilar substitution saves money
Pharmacist-driven biosimilar substitution saves money
GaBI
biosimilars
generics
pharmacists
ASCO
Flag link:
Include cancer patients in COVID-19 vaccine trials, say ASCO and Friends of Cancer Research
Include cancer patients in COVID-19 vaccine trials, say ASCO and Friends of Cancer Research
RAPS.org
cancer
ASCO
clinical trials
vaccines
COVID-19
patients
Flag link:
ASCO-Friends meeting: NCI offers strategies to modernize cancer trials
ASCO-Friends meeting: NCI offers strategies to modernize cancer trials
RAPS.org
ASCO
cancer
clinical trials
Flag link:
COVID-19 Pushes Cancer Conference Into a Virtual Format
COVID-19 Pushes Cancer Conference Into a Virtual Format
Motley Fool
COVID-19
ASCO
ASCO 2020
pandemic
conferences
Flag link:
Did cancer clinical trials stay on track at ASCO 2019?
Did cancer clinical trials stay on track at ASCO 2019?
Pharmaforum
ASCO
clinical trials
cancer
ASCO 2019
bladder cancer
breast cancer
prostate cancer
pancreatic cancer
Flag link:
Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs
Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs
BioCentury
FDA
ASCO
oncology
drug development
patients
clinical trials
tissue-agnostic drugs
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Yahoo/Benzinga
Motif Biosciences
Iclaprim
Merck
Keytruda
melanoma
JNJ
esketamine
ASCO
Pfizer
Veru. earnings
Aveo Pharmaceuticals
Calithera Biosciences
Flag link:
ASCO and Friends of Cancer Research Draft 5 Guidances for FDA
ASCO and Friends of Cancer Research Draft 5 Guidances for FDA
RAPS.org
ASCO
FDA
cancer
oncology
clinical trials
Friends of Cancer Research
Flag link:
Is ASCO Sending Mixed Messages On Cancer Drug Value?
Is ASCO Sending Mixed Messages On Cancer Drug Value?
Forbes
ASCO
cancer
oncology
value
drug pricing
Flag link:
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
Xconomy
ASCO
oncology
IDO inhibitors
Incyte
Flag link:
Does a Blue Ribbon Make This Biotech Stock a Buy Now?
Does a Blue Ribbon Make This Biotech Stock a Buy Now?
Motley Fool
Loxo Oncology
ASCO
LOXO-292
Flag link:
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Motley Fool
ASCO
Endocyte
Loxo Oncology
Blueprint Medicines
Nektar Therapeutics
Jounce Therapeutics
Flag link:
Syndax is hit with a setback during the ASCO preview round as lead drug flops in mid-stage study
Syndax is hit with a setback during the ASCO preview round as lead drug flops in mid-stage study
Endpoints
Syndax Pharma
HDAC inhibitors
entinostat
Keytruda
ASCO
Flag link:
Additional Results from Phase I Study Show Inovio's INO-5150 Stabilizing Effect on Prostate Cancer
Additional Results from Phase I Study Show Inovio's INO-5150 Stabilizing Effect on Prostate Cancer
CP Wire
Inovio
ASCO
prostate cancer
clinical trials
INO-5150
Flag link:
5 takeaways from the first look at cancer's biggest conference
5 takeaways from the first look at cancer's biggest conference
Biopharma Dive
ASCO
Regeneron
cemiplimab
Keytruda
Opdivo
Merck
Bristol-Myers Squibb
Nektar
NKTR-214
Loxo Oncology
LOXO-292
Jounce Therapeutics
JTX-2011
Flag link:
Deal struck to mine cancer patient database for new treatment insights
Deal struck to mine cancer patient database for new treatment insights
Stat
patients
cancer
ASCO
CancerLinQ
Flag link:

Pages